Browsing by Author "Martínez Marti, Alexandre"
Now showing items 1-14 of 14
-
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer
Herbst, Roy; Majem Tarruella, Margarita; Barlesi, Fabrice; Chu, Quincy; Monnet, Isabelle; Martínez Marti, Alexandre; Carcereny, Enric (American Society of Clinical Oncology, 2022-10-10) -
Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC
Carbonell, Caterina; Frigola Rissech, Joan; Pardo Aranda, Nuria; Callejo, Ana; Valdivia Bustamante, Augusto; Priano, Ilaria; Martínez Marti, Alexandre; Lenza, Laura; Soleda, Mireia; Gonzalo Ruiz, Javier; Amat Ferrer, Ramon; Iranzo, Patricia; cedres, susana; NAVARRO, ALEJANDRO; Vivancos, Ana; FELIP, ENRIQUETA (Wiley, 2023-05) -
Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain
de Castro Carpeno, Javier; Collado-Borell, Roberto; Martínez Marti, Alexandre; Fernández Díaz, Elena; Insa, Amelia; Escudero-Vilaplana, Vicente (BMC, 2023-02-21) -
Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
Cedres Perez, Susana; Assaf, Juan David; Iranzo Gómez, Patricia; Callejo Perez, Ana; Pardo Aranda, Nuria; Navarro Mendivil, Alejandro; Martínez Marti, Alexandre; Marmolejo Castañeda, David; Rezqallah Aron, Maria Alejandra; Amat, Ramon; Pedrola Gómez, Anna; Felip Font, Enriqueta; Carbonell, Caterina; Frigola Rissech, Joan; Dienstmann, Rodrigo (Nature Research, 2021-11-01) -
High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC
Iranzo Gómez, Patricia; Pardo Aranda, Nuria; Callejo Perez, Ana; Cedres Perez, Susana; Martínez Marti, Alexandre; Navarro Mendivil, Alejandro; Soleda, Mireia; Jiménez Flores, José Antonio; Hernandez Losa, Javier; Vivancos Prellezo, Ana; Felip Font, Enriqueta; Amat, Ramon; Carbonell, Caterina; Frigola Rissech, Joan (BMJ, 2022-04) -
Insight into the Role and Regulation of Gap Junction Genes in Lung Cancer and Identification of Nuclear Cx43 as a Putative Biomarker of Poor Prognosis
Sansano Valero, Irene; Montero Fernández, Maria Ángeles; Romagosa Pérez-Portabell, Cleofé; Temprana Salvador, Jordi; Martínez Marti, Alexandre; Moline Marimon, Teresa; Hernandez Losa, Javier; Ramon y Cajal Agüeras, Santiago; Aasen, Trond (MDPI, 2019-03-06) -
Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients
Callejo Perez, Ana; Iranzo Gómez, Patricia; Diaz-Mejia, Nely; Marmolejo Castañeda, David; Assaf, Juan David; Cedres Perez, Susana; Martínez Marti, Alexandre; Navarro Mendivil, Alejandro; Pardo Aranda, Nuria; Amat, Ramon; Felip Font, Enriqueta; Carbonell, Caterina; Frigola Rissech, Joan (MDPI, 2021-07) -
Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient
Domingues, I.; Cedres Perez, Susana; Callejo Perez, Ana; Vivancos Prellezo, Ana; Martínez Marti, Alexandre; Felip Font, Enriqueta (Elsevier, 2020-01) -
Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer
Navarro Mendivil, Alejandro; Callejo Perez, Ana; Iranzo Gómez, Patricia; Cedres Perez, Susana; Martínez Marti, Alexandre; Pardo Aranda, Nuria; Jiménez Flores, José Antonio; Sansano Valero, Irene; Mancuso, Francesco Mattia; Nuciforo, Paolo Giovanni; Vivancos Prellezo, Ana; Felip Font, Enriqueta; Amat, Ramon; Saoudi Gonzalez, Nadia; Carbonell, Caterina; Frigola Rissech, Joan (Wiley, 2021-04) -
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
Fernandes Neto, João M.; Bosdriesz, Evert; Ooft, Salo N.; Farre, Lourdes; McLean, Chelsea; Felip Font, Enriqueta; Martínez Marti, Alexandre; Nadal, Ernest (Nature Research, 2020-06-22) -
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
Serna-Blasco, Roberto; Garcia‑Campelo, Rosario; Casal Rubio, Joaquín; Martínez Marti, Alexandre; Insa, Amelia; Provencio, Mariano; Nadal, Ernest (American Society of Clinical Oncology, 2022-09-01) -
Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer
Iranzo Gómez, Patricia; Callejo Perez, Ana; Assaf Pastrana, Juan David; Molina, Gaspar; Lopez, Daniel Esteban; García Illescas, David; Pardo Aranda, Nuria; Navarro Mendivil, Alejandro; Martínez Marti, Alexandre; Cedres Perez, Susana; Amat, Ramon; Felip Font, Enriqueta; Carbonell, Caterina; Frigola Rissech, Joan (Frontiers Media, 2022-05-30) -
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Casarrubios García, Marta; Cruz-Bermúdez, Alberto; Martínez Marti, Alexandre; Martínez Marti, Alexandre; Insa, Amelia; Nadal, Ernest; Lázaro, Martín; Garcia Campelo, Rosario (American Association for Cancer Research, 2021-11-01) -
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
Casarrubios García, Marta; Garcia‑Campelo, Rosario; Martínez Marti, Alexandre; Insa, Amelia; Provencio, Mariano; Nadal, Ernest; Lázaro, Martín (BMJ, 2022-09)